PF161 THIOREDOXIN SYSTEM INHIBITORS ARE EFFECTIVE AGAINST B CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN VITRO AND IN VIVO
Klaudyna Fidyt(Polish Academy of Sciences), Małgorzata Firczuk(Medical University of Warsaw), Angelika Muchowicz(Medical University of Warsaw), Julia Cyran(Medical University of Warsaw), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), A. Burdzinska, Lukasz Komorowski(Medical University of Warsaw), Elżbieta Patkowska(Institute for Transfusion Medicine), Agnieszka Góral(Instytut Biologii Doświadczalnej im. Marcelego Nenckiego), Deepali Pal(Newcastle University), Piotr Pędzisz(Medical University of Warsaw), Agata Pastorczak(Medical University of Lodz), Helen J. Blair(APC Microbiome Institute), Wojciech Młynarski(Medical University of Silesia)
Cited by 0
Related Papers
<i>β</i>‐caryophyllene and <i>β</i>‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
|Cancer Medicine|2016|642
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213